More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes

Myelodysplastic syndromes (MDS) encompass a diverse group of hematologic disorders characterized by ineffective and malignant hematopoiesis, peripheral cytopenias and significantly increased risk of progression to acute myeloid leukemia (AML). The hypomethylating agents (HMA) azacitidine and decitab...

Descripción completa

Detalles Bibliográficos
Autores principales: Shallis, Rory M., Zeidan, Amer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796398/
https://www.ncbi.nlm.nih.gov/pubmed/29435332
http://dx.doi.org/10.1186/s12878-018-0095-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796398/
https://www.ncbi.nlm.nih.gov/pubmed/29435332
http://dx.doi.org/10.1186/s12878-018-0095-2

Ejemplares similares